C
Celosia Therapeutics
A privately held pre-clinical stage gene therapy company, developing solutions for neurodegenerative diseases that have limited alternative therapeutic options
About Celosia Therapeutics
Celosia Therapeutics is a pioneering biotech company focused on developing groundbreaking gene therapies to treat neurodegenerative diseases that currently lack effective therapeutic options. The company operates in the biotechnology and pharmaceutical market, primarily serving patients suffering from conditions such as ALS, MND, LGD disease, frontotemporal dementia, and Dravet Syndrome. Celosia Therapeutics leverages advances in gene therapy and a deeper understanding of molecular pathways to modify the neuronal microenvironment, aiming to significantly improve patient outcomes.
The business model of Celosia Therapeutics involves extensive research and development (R&D) to create innovative treatments, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, partnerships with pharmaceutical companies, and potential licensing agreements.
Celosia Therapeutics' team comprises scientists, clinicians, innovators, and entrepreneurs dedicated to redefining the treatment landscape for individuals with devastating neurodegenerative diseases. The company's mission is to change lives forever by providing new hope and effective solutions for patients and their families.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Sydney, Australia
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 69.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2024 | $11M | $43M | Iomar Barrett · UniSuper · Uniseed Ventures | ↗ |
| SEEDOther financing | Nov 2022 | $2M | $8M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Celosia Therapeutics is 450 monthly website visits, down 27.4% over the last three months. Celosia Therapeutics's team grew 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Celosia Therapeutics in the Sydney ecosystem
The Celosia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Uniseed Ventures- IBIomar Barrett
UniSuper
Other known investors1 additional known investor
Macquarie University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Celosia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Celosia Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










